Benjamin F. Edwards & Company’s Takeda Pharmaceutical TAK Stock Holding History

Benjamin F. Edwards & Company’s Portfolio TAK Stock Details TAK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	$22K	Buy	1,677 +194	+13%	+$2.57K	﹤0.01%	1526
2024 Q1	$21K	Buy	1,483 +216	+17%	+$3.14K	﹤0.01%	1520
2023 Q4	$18K	Buy	+1,267	New	+$18K	﹤0.01%	1514
2023 Q1	–	Sell	-145	Closed	-$2K	–	1901
2022 Q4	$2K	Buy	+145	New	+$2.02K	﹤0.01%	1751
2022 Q1	–	Sell	-297	Closed	-$4K	–	1834
2021 Q4	$4K	Hold	297	–	–	﹤0.01%	1572
2021 Q3	$5K	Hold	297	–	–	﹤0.01%	1542
2021 Q2	$5K	Hold	297	–	–	﹤0.01%	1528
2021 Q1	$5K	Hold	297	–	–	﹤0.01%	1519
2020 Q4	$5K	Hold	297	–	–	﹤0.01%	1417
2020 Q3	$5K	Sell	297 -353	-54%	-$6.43K	﹤0.01%	1450
2020 Q2	$12K	Buy	650 +283	+77%	+$5.08K	﹤0.01%	1248
2020 Q1	$6K	Hold	367	–	–	﹤0.01%	1405
2019 Q4	$7K	Hold	367	–	–	﹤0.01%	1529
2019 Q3	$6K	Hold	367	–	–	﹤0.01%	1550
2019 Q2	$6K	Sell	367 -848	-70%	-$15.4K	﹤0.01%	1573
2019 Q1	$25K	Buy	+1,215	New	+$24.4K	﹤0.01%	1076

Other funds holding TAK

GAM

Groupama Asset Management Paris, France $7.93B AUM 57.28% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

MIP

Mondrian Investment Partners London, United Kingdom $6.48B AUM 18.36% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

Benjamin F. Edwards & Company's TAK Position: Q2 2024 in Review

Benjamin F. Edwards & Company increased its Takeda Pharmaceutical (TAK) stake by 13% in Q2 2024, buying an estimated $2.57K and bringing the position to 1,677 shares worth $22K. The position accounts for ﹤0.01% of the portfolio, ranked #1526.

Benjamin F. Edwards & Company first reported a position in TAK in Q1 2019 and has held it in 16 quarters since. The position peaked at $25K in Q1 2019. 284 funds tracked by Wall St. Rank hold TAK as of Q2 2024.

Benjamin F. Edwards & Company held 1,677 shares of Takeda Pharmaceutical worth $22K as of Q2 2024.
Benjamin F. Edwards & Company bought 194 Takeda Pharmaceutical shares in Q2 2024, an estimated $2.57K.
Takeda Pharmaceutical made up ﹤0.01% of Benjamin F. Edwards & Company's portfolio in Q2 2024, its #1526 holding.
Benjamin F. Edwards & Company first reported a position in Takeda Pharmaceutical in Q1 2019 and has held it in 16 quarters since.
Benjamin F. Edwards & Company's Takeda Pharmaceutical position peaked at $25K in Q1 2019.
284 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q2 2024.

Based on Benjamin F. Edwards & Company's 13F filing for Q2 2024, filed 12 Aug 2024.